Daiichi Jitsugyo Co (8059) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Nov, 2025Executive summary
Achieved record-high net sales and profits at all levels for Q2 FY2025, driven by strong Automotive and Healthcare business performance and gains from investment securities sales.
Net sales for the six months ended September 30, 2025, rose 6.0% year-over-year to ¥107,326 million, with operating income up 7.6% to ¥6,591 million and profit attributable to owners of parent up 15.8% to ¥4,966 million.
Comprehensive income increased 23.1% year-over-year to ¥5,854 million.
Progress toward the upwardly revised full-year profit forecast reached 51.7% by Q2.
Financial highlights
Net sales rose by ¥6.038 billion year-over-year to ¥107.326 billion.
Operating income increased by ¥464 million YoY to ¥6.591 billion.
Profit attributable to owners of parent grew by ¥676 million YoY to ¥4.966 billion; EPS up ¥20.40 YoY to ¥155.63.
Gross profit increased by ¥885 million YoY to ¥18.766 billion.
Ordinary income increased 7.9% year-over-year to ¥6,705 million.
Outlook and guidance
FY2025 forecasts were revised upward; net sales forecast at ¥225 billion, operating income at ¥13.2 billion, ordinary income at ¥13.5 billion, and profit attributable to owners of parent at ¥9.6 billion.
Progress rates for these forecasts at Q2: net sales 47.7%, operating income 49.9%, ordinary income 49.7%, profit attributable to owners of parent 51.7%.
Basic earnings per share for the full year is forecast at ¥300.84.
Dividend forecast revised upward to ¥122.00 per share for the year, including a year-end dividend of ¥71.00.
Latest events from Daiichi Jitsugyo Co
- Record Q3 profits and strong segment growth support an upwardly revised full-year outlook.8059
Q3 20264 Feb 2026 - Record-high sales and profit, improved equity ratio, and strong full-year outlook.8059
Q2 20259 Sep 2025 - Record Q3 sales and profits, stock split, and strong growth across all segments.8059
Q3 20259 Sep 2025 - Record sales and profits, strong overseas growth, and a conservative outlook for next year.8059
Q4 20259 Sep 2025 - Record Q1 sales and profits driven by Healthcare and Automobile, but outlook is slightly cautious.8059
Q1 20269 Sep 2025 - Strong sales and profit growth, with robust outlook and improved equity ratio.8059
Q1 20259 Sep 2025